"instanceType","rationale","uuid:ID","name","id","description","label"
"StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","6d9332f0-565e-44bb-bf58-16f3daeb8c66","Study Design 1","StudyDesign_1","The main design for the study",""
